Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy
Open Access
- 1 August 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 122 (5) , 803-806
Abstract
Enterohemorrhagic Escherichia coli (EHEC) produce ribosome-inactivating Shiga toxins (Stx1, Stx2) responsible for development of hemolytic uremic syndrome (HUS) and acute kidney injury (AKI). Some patients show complement activation during EHEC infection, raising the possibility of therapeutic targeting of complement for relief. Our juvenile nonhuman primate (Papio baboons) models of endotoxin-free Stx challenge exhibit full spectrum HUS, including thrombocytopenia, hemolytic anemia, and AKI with glomerular thrombotic microangiopathy. There were no significant increases in soluble terminal complement complex (C5b-9) levels after challenge with lethal Stx1 (n = 6) or Stx2 (n = 5) in plasma samples from T0 to euthanasia at 49.5 to 128 hours post-challenge. d-dimer and cell injury markers (HMGB1, histones) confirmed coagulopathy and cell injury. Thus, complement activation is not required for the development of thrombotic microangiopathy and HUS induced by EHEC Shiga toxins in these preclinical models, and benefits or risks of complement inhibition should be studied further for this infection. Key Points Complement activation is not required for development of thrombotic microangiopathy and HUS induced by EHEC Shiga toxins in nonhuman primates. Complement is an important defense mechanism, and benefits or risks of therapeutic inhibition should be studied further for this infection.Keywords
This publication has 25 references indexed in Scilit:
- Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control studyBMJ, 2012
- Risk Factors for the Hemolytic Uremic Syndrome in Children Infected With Escherichia coli O157:H7: A Multivariable AnalysisClinical Infectious Diseases, 2012
- An Epidemiologic Surveillance of Shiga-like Toxin-producing Escherichia coli Infection in Argentinean ChildrenThe Pediatric Infectious Disease Journal, 2012
- Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptidePediatric Nephrology, 2011
- Interactions between coagulation and complement—their role in inflammationSeminars in Immunopathology, 2011
- Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular ThrombosisThe Journal of Immunology, 2011
- Eculizumab in Severe Shiga-Toxin–Associated HUSNew England Journal of Medicine, 2011
- Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical PhenotypeClinical Journal of the American Society of Nephrology, 2010
- Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsisBlood, 2010
- Distinct Physiologic and Inflammatory Responses Elicited in Baboons after Challenge with Shiga Toxin Type 1 or 2 from Enterohemorrhagic Escherichia coliInfection and Immunity, 2010